GREY:EPWCF - Post by User
Post by
Ergarets12on Dec 10, 2020 10:06am
114 Views
Post# 32076053
Developing a Treatment
Developing a Treatment
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in approx 40-50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse (early versus late) and the possibility of allogeneic hematopoietic stem cell transplantation (HSCT).
In AML patients relapsing after HSCT and good performance status, intensive therapy can be considered with subsequent cellular therapy such as donor lymphocyte infusion (DLI) or a second HSCT. However, less than approx 20% of these patients are alive after 5 years. For those patients that are unfit, the therapeutic aim is to prolong life with acceptable quality of life.
With this development treatment for leukemia patient would you support? Check disclaimer on profile